BCM
BVS icon

Bayesian Capital Management’s Bioventus BVS Stock Holding History

Bayesian Capital Management’s Portfolio BVS Stock Details BVS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-10,146
Closed -$92.8K – 571
2025
Q1 		$92.8K Buy
+10,146
New +$101K 0.02% 547

Other funds holding BVS

EWM
Essex Woodlands Management The Woodlands, Texas $251M AUM 13.72% 1-Year Est. Return
JIC
Juniper Investment Company New York $313M AUM 79.58% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $194B AUM 35% 1-Year Est. Return
RA
Royce & Associates New York $10.1B AUM 42.88% 1-Year Est. Return
DSCM
Divisadero Street Capital Management Miami, Florida $2.39B AUM 134.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Bayesian Capital Management's BVS Position: Q2 2025 in Review

Bayesian Capital Management sold out of Bioventus (BVS) in Q2 2025, closing a stake of 10,146 shares — an estimated $92.8K sold.

Bayesian Capital Management first reported a position in BVS in Q1 2025 and held it in 1 quarter. The position peaked at $92.8K in Q1 2025. 134 funds tracked by Wall St. Rank hold BVS as of Q2 2025.

  • Bayesian Capital Management reported no remaining Bioventus position as of Q2 2025 after selling out during the quarter.
  • Bayesian Capital Management sold 10,146 Bioventus shares in Q2 2025, an estimated $92.8K.
  • Bayesian Capital Management first reported a position in Bioventus in Q1 2025 and held it in 1 quarter.
  • Bayesian Capital Management's Bioventus position peaked at $92.8K in Q1 2025.
  • 134 funds tracked by Wall St. Rank held Bioventus as of Q2 2025.

Based on Bayesian Capital Management's 13F filing for Q2 2025, filed 14 Aug 2025.